Place of nanofiltration for assuring viral safety of biologicals

Thierry Pierre Robert Burnouf, M. Radosevich, Hadi Alphonse Goubran, Hannelore Willkommen

Research output: Contribution to journalArticle

Abstract

Viruses are nanometer size organisms (range from 18 to 250 nm) that can potentially contaminate the feedstocks from animal or human origins used to manufacture biopharmaceutical products. Various measures are taken to ensure the optimal viral safety of this class of products. Selection and screening of starting materials play an important role in safeguarding from the introduction of viruses into the downstream processing but they have limits in specificity and sensitivity. Purification methods of protein biopharmaceutical products may also contribute to viral reduction, but since viruses exhibit a wide range of biochemical characteristics and resistance to physico-chemical treatments, complete elimination of infectious agents is not guaranteed. Therefore, the viral safety of animal derived biopharmaceutical products is well recognized to rely largely upon the use of deliberately introduced and validated viral inactivation and/or removal steps. A major progress in viral safety has been made recently by the development and availability of biocompatible viral filtration (also known as nanofiltration) systems using membranes of a pore size as small as 15 nm; these systems are specifically designed to allow, depending upon membrane used, typically over 4 to 6 logs of virus removal under conditions ensuring good protein permeability and recovery. Validation studies and production experience throughout the world have demonstrated that viral nanofiltration is a robust and reliable viral reduction technique that can be applied to essentially all biological products. This review analyzes the virus risks of biopharmaceutical products (human plasma derivatives, horse and sheep plasma-derived products, recombinant proteins and monoclonal antibodies), the various viral inactivation methods used at present, and the increasing role that viral nanofiltration is playing in assuring the safety of biopharmaceutical products.
Original languageEnglish
JournalCurrent Nanoscience
Publication statusPublished - 2005
Externally publishedYes

Fingerprint

Nanofiltration
Viruses
Safety
Virus Inactivation
Animals
Plasma (human)
Proteins
Membranes
Recombinant proteins
Monoclonal antibodies
Validation Studies
Biological Products
Recombinant Proteins
Feedstocks
Horses
Pore size
Purification
Permeability
Sheep
Screening

Cite this

Place of nanofiltration for assuring viral safety of biologicals. / Burnouf, Thierry Pierre Robert; Radosevich, M.; Goubran, Hadi Alphonse; Willkommen, Hannelore.

In: Current Nanoscience, 2005.

Research output: Contribution to journalArticle

Burnouf, Thierry Pierre Robert ; Radosevich, M. ; Goubran, Hadi Alphonse ; Willkommen, Hannelore. / Place of nanofiltration for assuring viral safety of biologicals. In: Current Nanoscience. 2005.
@article{8e6b21e25ccf4b4cb3432d84c101d62a,
title = "Place of nanofiltration for assuring viral safety of biologicals",
abstract = "Viruses are nanometer size organisms (range from 18 to 250 nm) that can potentially contaminate the feedstocks from animal or human origins used to manufacture biopharmaceutical products. Various measures are taken to ensure the optimal viral safety of this class of products. Selection and screening of starting materials play an important role in safeguarding from the introduction of viruses into the downstream processing but they have limits in specificity and sensitivity. Purification methods of protein biopharmaceutical products may also contribute to viral reduction, but since viruses exhibit a wide range of biochemical characteristics and resistance to physico-chemical treatments, complete elimination of infectious agents is not guaranteed. Therefore, the viral safety of animal derived biopharmaceutical products is well recognized to rely largely upon the use of deliberately introduced and validated viral inactivation and/or removal steps. A major progress in viral safety has been made recently by the development and availability of biocompatible viral filtration (also known as nanofiltration) systems using membranes of a pore size as small as 15 nm; these systems are specifically designed to allow, depending upon membrane used, typically over 4 to 6 logs of virus removal under conditions ensuring good protein permeability and recovery. Validation studies and production experience throughout the world have demonstrated that viral nanofiltration is a robust and reliable viral reduction technique that can be applied to essentially all biological products. This review analyzes the virus risks of biopharmaceutical products (human plasma derivatives, horse and sheep plasma-derived products, recombinant proteins and monoclonal antibodies), the various viral inactivation methods used at present, and the increasing role that viral nanofiltration is playing in assuring the safety of biopharmaceutical products.",
author = "Burnouf, {Thierry Pierre Robert} and M. Radosevich and Goubran, {Hadi Alphonse} and Hannelore Willkommen",
year = "2005",
language = "English",
journal = "Current Nanoscience",
issn = "1573-4137",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Place of nanofiltration for assuring viral safety of biologicals

AU - Burnouf, Thierry Pierre Robert

AU - Radosevich, M.

AU - Goubran, Hadi Alphonse

AU - Willkommen, Hannelore

PY - 2005

Y1 - 2005

N2 - Viruses are nanometer size organisms (range from 18 to 250 nm) that can potentially contaminate the feedstocks from animal or human origins used to manufacture biopharmaceutical products. Various measures are taken to ensure the optimal viral safety of this class of products. Selection and screening of starting materials play an important role in safeguarding from the introduction of viruses into the downstream processing but they have limits in specificity and sensitivity. Purification methods of protein biopharmaceutical products may also contribute to viral reduction, but since viruses exhibit a wide range of biochemical characteristics and resistance to physico-chemical treatments, complete elimination of infectious agents is not guaranteed. Therefore, the viral safety of animal derived biopharmaceutical products is well recognized to rely largely upon the use of deliberately introduced and validated viral inactivation and/or removal steps. A major progress in viral safety has been made recently by the development and availability of biocompatible viral filtration (also known as nanofiltration) systems using membranes of a pore size as small as 15 nm; these systems are specifically designed to allow, depending upon membrane used, typically over 4 to 6 logs of virus removal under conditions ensuring good protein permeability and recovery. Validation studies and production experience throughout the world have demonstrated that viral nanofiltration is a robust and reliable viral reduction technique that can be applied to essentially all biological products. This review analyzes the virus risks of biopharmaceutical products (human plasma derivatives, horse and sheep plasma-derived products, recombinant proteins and monoclonal antibodies), the various viral inactivation methods used at present, and the increasing role that viral nanofiltration is playing in assuring the safety of biopharmaceutical products.

AB - Viruses are nanometer size organisms (range from 18 to 250 nm) that can potentially contaminate the feedstocks from animal or human origins used to manufacture biopharmaceutical products. Various measures are taken to ensure the optimal viral safety of this class of products. Selection and screening of starting materials play an important role in safeguarding from the introduction of viruses into the downstream processing but they have limits in specificity and sensitivity. Purification methods of protein biopharmaceutical products may also contribute to viral reduction, but since viruses exhibit a wide range of biochemical characteristics and resistance to physico-chemical treatments, complete elimination of infectious agents is not guaranteed. Therefore, the viral safety of animal derived biopharmaceutical products is well recognized to rely largely upon the use of deliberately introduced and validated viral inactivation and/or removal steps. A major progress in viral safety has been made recently by the development and availability of biocompatible viral filtration (also known as nanofiltration) systems using membranes of a pore size as small as 15 nm; these systems are specifically designed to allow, depending upon membrane used, typically over 4 to 6 logs of virus removal under conditions ensuring good protein permeability and recovery. Validation studies and production experience throughout the world have demonstrated that viral nanofiltration is a robust and reliable viral reduction technique that can be applied to essentially all biological products. This review analyzes the virus risks of biopharmaceutical products (human plasma derivatives, horse and sheep plasma-derived products, recombinant proteins and monoclonal antibodies), the various viral inactivation methods used at present, and the increasing role that viral nanofiltration is playing in assuring the safety of biopharmaceutical products.

M3 - Article

JO - Current Nanoscience

JF - Current Nanoscience

SN - 1573-4137

ER -